Top immuno-oncology insights of 2025: data that will transform your preclinical research

Take a deeper dive into the science behind our immuno-oncology models and how they will improve your chances of success

‍

Explore how ourmodels can help advance your immuno-oncology research:

‍

1. Efficacy and safety assessment of T-cell engagers (TCEs) with humanized CD3 mice

• Watch the webinar about the development of these models, and how they enabled developers of new therapeutics to successfully test their TCEs, helping them to advance to clinical trials: 

‍

Testing an antibody targeting human CCR8 with a Fc-competent domain?

You might not be capturing the contribution of the effector function of your antibody if you are not using a model with humanized Fcγ receptors.

We crossed our genO-hCCR8/hCCL1 model with the extensively validated genO-hFcγR model, to enable you to test antibodies with an Fc competent domain and acquire a more complete and translatable readout of the efficacy of your therapeutic.  

This is a unique model, featuring:  

• A human-like expression pattern of hFcγ receptors and of hCCR8 and hCCL1

• Functional receptors, enabling assessment of Fc-mediated effector functions

• Functional CCR8/CCL1 signalling axis

• No expression of murine FcγR

• A fully functional mouse immune system

‍

‍

We also have other models available for testing Treg-depleting therapeutics:

• genO-BRGSF-HIS
• genO-hCTLA-4
• genO-hOX40
• genO-hGITR